Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Bonini SA, Memo M.

Neurochem Res. 2007 Oct;32(10):1726-9. Epub 2007 May 8. Review.

PMID:
17486445
2.

Dopamine receptor agonists for protection and repair in Parkinson's disease.

Ferrari-Toninelli G, Bonini SA, Cenini G, Maccarinelli G, Grilli M, Uberti D, Memo M.

Curr Top Med Chem. 2008;8(12):1089-99. Review.

PMID:
18691134
3.

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

Radad K, Gille G, Rausch WD.

Pharmacol Rep. 2005 Nov-Dec;57(6):701-12. Review.

4.

Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.

Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA.

Neuropsychologia. 2009 Apr;47(5):1374-81. doi: 10.1016/j.neuropsychologia.2009.01.039. Epub 2009 Feb 7.

PMID:
19428401
5.

Dopamine receptors--physiological understanding to therapeutic intervention potential.

Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S.

Pharmacol Ther. 1999 Nov;84(2):133-56. Review.

PMID:
10596903
6.

Receptor-binding and pharmacokinetic properties of dopaminergic agonists.

Kvernmo T, Houben J, Sylte I.

Curr Top Med Chem. 2008;8(12):1049-67. Review.

PMID:
18691132
7.

D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.

Lewis MM, Huang X, Nichols DE, Mailman RB.

CNS Neurol Disord Drug Targets. 2006 Jun;5(3):345-53. Review.

PMID:
16787233
8.

Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.

Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A.

Behav Pharmacol. 2009 Jul;20(4):303-11. doi: 10.1097/FBP.0b013e32832ec5aa.

PMID:
19584712
9.

Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.

Joyce JN, Millan MJ.

Curr Opin Pharmacol. 2007 Feb;7(1):100-5. Epub 2006 Dec 13. Review.

PMID:
17174156
10.

Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.

Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M.

J Neurosci Res. 2008 Feb 15;86(3):640-6.

PMID:
17896793
11.

Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.

Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, Shimizu T, Ueno S.

Clin Neurol Neurosurg. 2009 May;111(4):341-4. doi: 10.1016/j.clineuro.2008.11.007. Epub 2008 Dec 20.

PMID:
19097685
12.
13.

Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.

Shin JY, Park HJ, Ahn YH, Lee PH.

J Neurochem. 2009 Nov;111(4):1042-50. doi: 10.1111/j.1471-4159.2009.06381.x. Epub 2009 Sep 16.

14.

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

Gribkoff VK, Bozik ME.

CNS Neurosci Ther. 2008 Fall;14(3):215-26. doi: 10.1111/j.1755-5949.2008.00048.x. Review.

PMID:
18801114
15.

Role of dopamine agonists in Parkinson's disease: an update.

Bonuccelli U, Pavese N.

Expert Rev Neurother. 2007 Oct;7(10):1391-9. Review.

PMID:
17939774
16.

Neuroprotective effects of D3 dopamine receptor agonists.

Carvey PM, McGuire SO, Ling ZD.

Parkinsonism Relat Disord. 2001 Jul;7(3):213-223.

PMID:
11331189
17.

Dopamine receptor agonists for Parkinson's disease.

Blandini F, Armentero MT.

Expert Opin Investig Drugs. 2014 Mar;23(3):387-410. doi: 10.1517/13543784.2014.869209. Epub 2013 Dec 9. Review.

PMID:
24313341
18.

Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs.

Mercuri NB, Bonci A, Bernardi G.

Trends Pharmacol Sci. 1997 Jul;18(7):232-5. Review.

PMID:
9253853
19.

Drugs used to treat Parkinson's disease, present status and future directions.

Abdel-Salam OM.

CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. Review.

PMID:
18991661
20.

Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.

Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P.

J Neurochem. 2008 Jul;106(2):560-77. doi: 10.1111/j.1471-4159.2008.05406.x. Epub 2008 Apr 10.

Supplemental Content

Support Center